Alebund Pharmaceuticals Begins Global Phase IIb Trial for AP306

AP306 distinguishes itself from traditional phosphate binders by acting as a pan-phosphate transporter inhibitor. Instead of binding phosphate in the gut lumen, the drug inhibits three primary intestinal transporters—NaPi-IIb, PiT-1, and PiT-2—to block active phosphate absorption. This mechanism aims to address the significant unmet needs in chronic kidney disease management, where current therapies often struggle with patient adherence, gastrointestinal side effects, and pill burden.

The double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of six fixed-dose regimens over an eight-week treatment period. Researchers have identified the change in serum phosphate from baseline as the primary endpoint, with topline results anticipated in the first half of 2027. Previous clinical data from China, published in Kidney International Reports, showed that AP306 reduced serum phosphate levels by a mean of 2.51 mg/dL, outperforming sevelamer carbonate in a comparative study.

Hyperphosphatemia remains a critical complication for dialysis patients, with failure rates for reaching target phosphate ranges reaching 76% in China and 52% in the United States. Following the drug's designation as a Breakthrough Therapy by China's National Medical Products Administration in 2024, Alebund and R1 Therapeutics are coordinating clinical execution across their respective territories. The trial is currently active, with enrollment underway at sites including Peking University People's Hospital.